Jagsonpal Pharma Reports Q4 Profit Surge, Declares Dividend, and Terminates Business Transfer Agreement
Jagsonpal Pharmaceuticals Limited reported a significant increase in Q4 net profit, rising 85.9% year-on-year to ₹66.00 million. Revenue also grew by 34.7% to ₹586.00 million. The company declared a dividend of ₹2.50 per equity share. However, Q4 profit decreased from ₹320.00 million in the previous quarter. Jagsonpal also announced the termination of a business transfer agreement for the acquisition of Resilient due to unmet conditions.
06May 25
Jagsonpal Pharma Cancels Acquisition of Resilient as Business Transfer Agreement Terminated
Jagsonpal Pharmaceuticals Limited has announced the termination of its business transfer agreement for the acquisition of Resilient. The decision was reached mutually between Jagsonpal Pharma and the seller due to unfulfilled conditions precedent. This development marks a significant change in Jagsonpal Pharma's strategic plans, potentially affecting its expansion strategy. The company will need to reassess its growth plans in light of this cancellation.
Jagsonpal Pharmaceuticals Limited has reported impressive Q4 financial results. Revenue increased by 34.74% to ₹586.00 crore, while net profit surged by 85.92% to ₹66.00 crore. EBITDA showed a remarkable growth of 225.96%, reaching ₹87.00 crore. The company's EBITDA margin expanded to 14.85% from 6.14%. Additionally, Jagsonpal Pharma announced a dividend of ₹2.50 per equity share.
02Apr 25
Jagsonpal Pharma Faces ₹10.19 Crore Customs Duty Demand and Penalty
Jagsonpal Pharmaceuticals has received a customs order confirming a differential duty of ₹5.09 crore and an equivalent penalty, totaling ₹10.19 crore. The demand stems from an alleged incorrect classification of imported goods. The company maintains it has followed the correct classification and plans to file an appeal, believing it has merits in the case and does not expect any material financial impact.
21Feb 25
Jagsonpal Pharmaceuticals Expands Portfolio with ₹24 Crore Acquisition of Resilient Cosmeceuticals' India Business
Jagsonpal Pharmaceuticals has signed a Business Transfer Agreement to acquire Resilient Cosmeceuticals' India business for ₹24 crore. The deal, expected to close within 45 days, will be funded through internal accruals. This acquisition expands Jagsonpal's portfolio in Pharmaceuticals, Nutritional, and Cosmetic products, strengthening its position in Gynaecology and Dermatology. The move is set to enhance Jagsonpal's market presence, particularly in Maharashtra, Karnataka, and Kerala, and is projected to improve its market ranking from 75th to 71st in the pharmaceutical sector.
21Feb 25
Jagsonpal Pharmaceuticals Faces FDA Warning: Potential Impact on US Sales
Jagsonpal Pharmaceuticals has received a warning letter from the U.S. FDA dated February 5, 2025, citing CGMP violations and registration issues at a contract manufacturing facility. The company disclosed potential sales loss of 35 million INR (1.46% of annual sales) due to this warning. Jagsonpal currently supplies only one OTC API to the U.S. market. The company informed stock exchanges on February 21, 2025, in compliance with SEBI regulations.